KTRA - Kintara Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

with an average price target of $120.48. This is a potential upside of $114.18 (1812.38%) from yesterday's end of day stock price of $6.3.

Kintara Therapeutics's activity chart (see below) currently has 0 price targets and 3 ratings on display.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 33.33% with an average time for these price targets to be met of 76 days.

Most recent stock forecast was given by JASON MCCARTHY from MAXIM GROUP on 14-Jul-2023. First documented stock forecast 06-Sep-2019.

Best performing analysts who are covering KTRA - Kintara Therapeutics:

Jason Mccarthy Nathan Weinstein

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$14

$7.7 (122.22%)

2 years 8 days ago
(14-Jul-2023)

2/3 (66.67%)

$9.36 (201.72%)

152

Buy

$300

$295.96 (7325.74%)

4 years 10 months 8 days ago
(14-Sep-2020)

0/1 (0%)

$219 (270.37%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is KTRA (Kintara Therapeutics) average time for price targets to be met?

On average it took 76 days on average for the stock forecasts to be realized with a an average price target met ratio 33.33

Which analyst has the current highest performing score on KTRA (Kintara Therapeutics) with a proven track record?

JASON MCCARTHY

Which analyst has the current lower performing score on KTRA (Kintara Therapeutics) with a proven track record?

NATHAN WEINSTEIN

Which analyst has the most public recommendations on KTRA (Kintara Therapeutics)?

Jason Mccarthy works at MAXIM GROUP and has 2 price targets and 2 ratings on KTRA

Which analyst is the currently most bullish on KTRA (Kintara Therapeutics)?

Nathan Weinstein with highest potential upside - $295.96

Which analyst is the currently most reserved on KTRA (Kintara Therapeutics)?

Jason Mccarthy with lowest potential downside - $7.7

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?